MX2020004730A - Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada. - Google Patents

Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.

Info

Publication number
MX2020004730A
MX2020004730A MX2020004730A MX2020004730A MX2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A MX 2020004730 A MX2020004730 A MX 2020004730A
Authority
MX
Mexico
Prior art keywords
intraocular pressure
sustained
effect
extended duration
lowering intraocular
Prior art date
Application number
MX2020004730A
Other languages
English (en)
Spanish (es)
Inventor
Michael R Robinson
Marina Bejanian
Michelle Y Chen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2020004730A publication Critical patent/MX2020004730A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
MX2020004730A 2017-11-09 2018-11-09 Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada. MX2020004730A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US201862683337P 2018-06-11 2018-06-11
PCT/US2018/059910 WO2019094652A1 (en) 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Publications (1)

Publication Number Publication Date
MX2020004730A true MX2020004730A (es) 2020-08-13

Family

ID=64457124

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004730A MX2020004730A (es) 2017-11-09 2018-11-09 Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
MX2023011426A MX2023011426A (es) 2017-11-09 2020-07-13 Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011426A MX2023011426A (es) 2017-11-09 2020-07-13 Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.

Country Status (16)

Country Link
US (2) US20190192341A1 (https=)
EP (1) EP3706717A1 (https=)
JP (2) JP2021502366A (https=)
KR (1) KR20200086289A (https=)
CN (1) CN111315361A (https=)
AU (2) AU2018366214B2 (https=)
BR (1) BR112020009224A2 (https=)
CA (1) CA3080908A1 (https=)
CL (1) CL2020001183A1 (https=)
CO (1) CO2020006924A2 (https=)
IL (1) IL273946A (https=)
MX (2) MX2020004730A (https=)
PH (1) PH12020550550A1 (https=)
RU (1) RU2020113494A (https=)
SG (1) SG11202004126XA (https=)
WO (1) WO2019094652A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2022011321A1 (en) 2020-07-10 2022-01-13 Allergan, Inc. Posterior chamber delivery device for sustained release implant
BR112023001073A2 (pt) * 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
EP3085358B1 (en) * 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
EP3324890A4 (en) * 2015-07-23 2019-06-19 Allergan, Inc. GLACO-TREATMENT VIA INTRAKAMERAL EYE IMPLANTS

Also Published As

Publication number Publication date
CA3080908A1 (en) 2019-05-16
BR112020009224A2 (pt) 2020-10-13
MX2023011426A (es) 2023-10-17
US20240130890A1 (en) 2024-04-25
JP2024032731A (ja) 2024-03-12
JP2021502366A (ja) 2021-01-28
CO2020006924A2 (es) 2020-06-19
CN111315361A (zh) 2020-06-19
AU2018366214A1 (en) 2020-05-14
PH12020550550A1 (en) 2021-03-22
RU2020113494A3 (https=) 2021-12-09
IL273946A (en) 2020-05-31
RU2020113494A (ru) 2021-12-09
KR20200086289A (ko) 2020-07-16
EP3706717A1 (en) 2020-09-16
US20190192341A1 (en) 2019-06-27
WO2019094652A1 (en) 2019-05-16
AU2018366214B2 (en) 2024-11-14
CL2020001183A1 (es) 2020-11-06
SG11202004126XA (en) 2020-06-29
US20240225893A9 (en) 2024-07-11
AU2024227541A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
MX2020004730A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
EP3863658C0 (en) OPHTHALMIC COMPOSITION FOR THE TREATMENT OF DRY EYE
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
PH12018500658A1 (en) Methods of treating intraocular pressure with activators of tie-2
MX2020004076A (es) Composiciones oftalmicas estabilizadas de omega 3.
IL277557A (en) Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.
MX387839B (es) Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
EA201790383A1 (ru) Композиции и способы лечения и профилактики инфекций области хирургического вмешательства
GB2541840A (en) Ophthalmic composition for the treatment of ocular infection
MX385405B (es) Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.
MX391659B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
EA035539B9 (ru) Офтальмологическая композиция для применения при лечении офтальмологических расстройств, связанных с изменениями роговично-конъюнктивальной поверхности
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
RU2014140798A (ru) Способ коррекции фиброзно-измененных фильтрационных подушек, возникающих в послеоперационном периоде при хирургии глаукомы
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
WO2016069950A3 (en) Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1)
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
WO2015200601A3 (en) Lymphangiogenesis inhibitors for cancer and for graft survival
ES1240340Y (es) Implante de drenaje en el tratamiento del glaucoma por el procedimiento de esclerectomia profunda no perforante